BR0016111A - Derivados de triazaespiro[5,5]undecano e medicamentos contendo os mesmos como ingrediente ativo - Google Patents

Derivados de triazaespiro[5,5]undecano e medicamentos contendo os mesmos como ingrediente ativo

Info

Publication number
BR0016111A
BR0016111A BR0016111-0A BR0016111A BR0016111A BR 0016111 A BR0016111 A BR 0016111A BR 0016111 A BR0016111 A BR 0016111A BR 0016111 A BR0016111 A BR 0016111A
Authority
BR
Brazil
Prior art keywords
triazaspiro
derivatives
active ingredient
medicines containing
undecane derivatives
Prior art date
Application number
BR0016111-0A
Other languages
English (en)
Inventor
Hiromu Habashita
Shin-Ichi Hamano
Shiro Shibayama
Yashikazu Takaoka
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BR0016111A publication Critical patent/BR0016111A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE TRIAZAESPIRO[5,5] UNDECANO E MEDICAMENTOS CONTENDO OS MESMOS COMO INGREDIENTE ATIVO". Derivados de triazaespiro[5,5] undecano representados pela fórmula geral (I), sais de amónio quaternário, Nóxidos e sais não tóxicos dos mesmos, onde cada símbolo possui o significado definido na descrição. Em razão do controle do efeito das quimocinas/reguladores de quimocinas, os compostos representados pela fórmula (I) são úteis na prevenção e/ou tratamento de várias doenças inflamatórias, asma, dermatite atópica, urticária, doenças alérgicas, nefrite, nefropatia, hepatite, artrite, artrite reumatóide, etc.
BR0016111-0A 1999-12-03 2000-12-01 Derivados de triazaespiro[5,5]undecano e medicamentos contendo os mesmos como ingrediente ativo BR0016111A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP34496799 1999-12-03
JP2000018673 2000-01-27
JP2000027968 2000-02-04
JP2000147882 2000-05-19
PCT/JP2000/008517 WO2001040227A1 (fr) 1999-12-03 2000-12-01 Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif

Publications (1)

Publication Number Publication Date
BR0016111A true BR0016111A (pt) 2003-03-25

Family

ID=27480653

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016111-0A BR0016111A (pt) 1999-12-03 2000-12-01 Derivados de triazaespiro[5,5]undecano e medicamentos contendo os mesmos como ingrediente ativo

Country Status (18)

Country Link
US (1) US7119091B2 (pt)
EP (1) EP1236726B1 (pt)
JP (1) JP4721087B2 (pt)
KR (1) KR100613176B1 (pt)
CN (1) CN1246321C (pt)
AT (1) ATE283854T1 (pt)
AU (1) AU780419C (pt)
BR (1) BR0016111A (pt)
CA (1) CA2394679A1 (pt)
DE (1) DE60016454T2 (pt)
ES (1) ES2233479T3 (pt)
HU (1) HUP0300641A2 (pt)
MX (1) MXPA02005465A (pt)
NO (1) NO323631B1 (pt)
NZ (1) NZ519183A (pt)
PT (1) PT1236726E (pt)
TW (1) TWI224597B (pt)
WO (1) WO2001040227A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2266452T3 (es) 2001-03-19 2007-03-01 Ono Pharmaceutical Co., Ltd. Derivados de triazaespiro (5.5) undecano y composiciones farmaceuticas que los contienen como ingrediente activo.
WO2002074769A1 (fr) * 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane
CN1571671A (zh) * 2001-10-23 2005-01-26 小野药品工业株式会社 含三氮杂螺[5.5]十一烷衍生物与细胞色素p450同工酶3a4抑制剂和/或p－糖蛋白抑制剂组合的药剂
AU2003211427A1 (en) * 2002-02-18 2003-09-04 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
CN1688577A (zh) * 2002-09-18 2005-10-26 小野药品工业株式会社 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
EP1541573A4 (en) 2002-09-18 2007-05-02 Ono Pharmaceutical Co NEW CRYSTALS OF DERIVATIVE TRIAZASPIRO 5.5 | UNDECANES
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
AU2003289329A1 (en) * 2002-12-13 2004-07-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist binding to strong binding site of chemokine receptor
EP1569647B1 (en) 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EP1621540A4 (en) * 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
WO2005075484A2 (en) 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
AU2005251891A1 (en) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-C] derivatives and their use as antiviral compounds
NZ551603A (en) * 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
JP2008504280A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
KR20070024639A (ko) * 2004-06-24 2007-03-02 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도
MX2007001540A (es) * 2004-08-10 2007-04-23 Incyte Corp Compuestos amido y sus usos como farmaceuticos.
KR101231466B1 (ko) 2004-09-13 2013-02-07 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
US20060160859A1 (en) * 2004-12-01 2006-07-20 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW873140
EP2527337A1 (en) * 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
CA2644368A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2051977A2 (en) * 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
CN101646679A (zh) 2007-03-29 2010-02-10 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
IN2012DN00352A (pt) * 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
RU2569061C2 (ru) 2010-02-03 2015-11-20 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US20130196990A1 (en) 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
EP2932533A4 (en) 2012-12-13 2016-08-10 Daniel S Marshall MAGNETICALLY POLARIZED PHOTONIC DEVICE
CA3034211A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
CN108727400B (zh) * 2017-05-24 2021-07-09 四川晶华生物科技有限公司 一种治疗肿瘤的化合物
CN107216335B (zh) * 2017-06-29 2019-04-30 上海药明康德新药开发有限公司 一种叔丁基1-(羟甲基)-3-氧杂-9-氮杂螺[5.5]十一烷-9-甲酸基酯制法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS231227B1 (en) * 1982-10-01 1984-10-15 Evzen Kasafirek 2,5-pierazindion derivatives
CS260899B1 (en) * 1986-11-07 1989-01-12 Evzen Kasafirek Remedy for gastrointestinal diseases
WO1993013101A1 (en) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
NO20022609L (no) 2002-07-26
JP4721087B2 (ja) 2011-07-13
CN1433419A (zh) 2003-07-30
NO323631B1 (no) 2007-06-18
AU780419C (en) 2005-09-29
ATE283854T1 (de) 2004-12-15
US7119091B2 (en) 2006-10-10
EP1236726B1 (en) 2004-12-01
CA2394679A1 (en) 2001-06-07
KR20030003218A (ko) 2003-01-09
US20040097511A1 (en) 2004-05-20
MXPA02005465A (es) 2003-10-15
PT1236726E (pt) 2005-04-29
HUP0300641A2 (hu) 2003-06-28
AU1650601A (en) 2001-06-12
EP1236726A4 (en) 2003-01-15
KR100613176B1 (ko) 2006-08-17
NO20022609D0 (no) 2002-05-31
NZ519183A (en) 2005-02-25
AU780419B2 (en) 2005-03-17
CN1246321C (zh) 2006-03-22
DE60016454D1 (de) 2005-01-05
ES2233479T3 (es) 2005-06-16
EP1236726A1 (en) 2002-09-04
WO2001040227A1 (fr) 2001-06-07
DE60016454T2 (de) 2005-08-04
TWI224597B (en) 2004-12-01

Similar Documents

Publication Publication Date Title
BR0016111A (pt) Derivados de triazaespiro[5,5]undecano e medicamentos contendo os mesmos como ingrediente ativo
DK1378510T3 (da) Triazaspiro[5.5]undecan-derivater og lægemidler indeholdende disse som en aktiv bestanddel
BR0314304A (pt) Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo
NO942977L (no) Piperazin og piperidinderivater og anvendelse derav som antipsykotiske midler
BR9811555A (pt) 2-aminopiridinas contendo anéis substituintes fundidos como inibidores nos
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR9913097A (pt) Agente antiviral, e, derivado heterocìclico de carboxamida contendo nitrogênio
PT1256588E (pt) Derivados de pirazina originais ou os seus sais, preparacoes farmaceuticas, contendo os derivados ou os seus sais e produtos intermedios para a preparacao de ambos
NO20054763L (no) Salter av clopidogrel og fremgangsmate for fremstilling derav
HRP20050123B1 (hr) Kompozicija i antivirusna aktivnost supstituiranih azaindoloksooctenih piperazin derivata
NO972910L (no) Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister
ES2178668T4 (es) Naftilamidas como agentes del sistema nervioso central.
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
DE60335911D1 (de) Isochinolinonderivate und deren verwendung als medikamente
BR0114754A (pt) Compostos não-imidazóis
BR0209518A (pt) Novos derivados arilheteroalquilamina
TR200200716T2 (tr) Ketiyapin granülleri
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
BR0213037A (pt) Derivados de pirimidina
BR0316108A (pt) Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
ES2086579T3 (es) Antagonista de leucotrieno b4.
BR0112131A (pt) Composições farmacêuticas e métodos para uso
NO982863L (no) Nye forbindelser med analgetisk effekt
TW200505448A (en) 5-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.